The lower urinary tract symptoms (LUTS) are very common in men, particularly in people over 65 years. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in males, and is a common cause of impaired quality of life. Alpha blockers monotherapy represent the treatment of choice in patients with moderate-severe LUTS secondary to BPH. Silodosin is currently the most α1A uroselective alpha blocker, uroselectivity which has been confirmed in several studies both in vitro and in vivo. In this paper the main benefits of silodosin are analyzed in both phase III clinical trials (standard approach) as in "real life" (analyzing the study SiRE [Silodosin in Real-life Evaluation], phase IV study), to validate the test data recording and confirm the positive benefit-risk profile of silodosin in a context that can reflect more closely the clinical practice.
Semergen. 2016 Jul [Epub]
A Alcántara Montero, Grupo de Trabajo de Nefrourología de SEMERGEN
Centro de Salud José María Álvarez, Don Benito, Badajoz, España. Electronic address: ., Centro de Salud José María Álvarez, Don Benito, Badajoz, España.